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A
 
ccording to WHO statistics, in 1996 875,000 new
cases of colorectal cancer were diagnosed and 495,000
deaths were attributed to it worldwide (1). It is the third
most common cause of cancer deaths and its incidence and
mortality rates continue to rise.
Most colorectal cancers develop via a characteristic series
of pathological steps (Fig. 1). Colorectal epithelial cells ac-
quire abnormal growth and morphological characteristics
and form an adenoma, a tumor mass often protruding into
the lumen of the colon or rectum. In time, these lesions
enlarge and a subset of cells can acquire additional abnor-
mal growth behaviors, which allows them to invade into
the bowel wall and metastasize. At this point, the tumors
are classified as adenocarcinomas and can be lethal. In the
course of this typical multistep process, somatic mutations
develop in key genes in the cells that comprise these le-
sions, such as in: the adenomatous polyposis coli (APC) and
 
p53 tumor suppressor genes; the Ki-
 
ras
 
 oncogene; and var-
ious genes that mediate DNA mismatch repair (2). The
mutational events presumably drive the evolution of the
pathological lesions and their neoplastic and malignant be-
havior.
Considerable evidence supports the view that aspirin
(ASA) and other nonsteroidal antiinflammatory drugs
(NSAIDs) prevent colorectal cancer (3). A combination of
epidemiological, animal, and basic studies make a compel-
ling case that regular use of these compounds lowers the
risk for the development of colorectal cancer, as well as ad-
enomas. Recently, sulindac was also shown to eliminate
aberrant crypt foci in the colorectum of patients who have
had adenomatous polyps. These lesions are similar to ade-
nomas but are not yet visible to the naked eye, and proba-
bly grow to become adenomas (4). Overall, the weight of
the evidence indicates that NSAIDs are the preeminent
colorectal cancer chemopreventive agents. It is of para-
mount importance, then, to identify their mechanism of
action in the chemoprevention of colorectal cancer.
NSAIDs inhibit the catalytic activity of cyclooxygenase
(COX, more properly called prostaglandin H synthase, or
PGHS), and this is thought to be the predominant mecha-
nism by which they act as analgesic, antipyretic, and antiin-
flammatory agents (Fig. 2). Reports indicating that ASA
and other NSAIDs inhibit colon carcinogenesis provided
the impetus for a series of studies showing that the levels of
 
both PGE
 
2
 
 and COX-2 are augmented in human colon
cancer (for review see reference 3). As a result, it generally
has been assumed that the antineoplastic effects of NSAIDs
were dependent upon inhibition of COX activity and PG
synthesis. Yet evidence is mounting that NSAIDs produce
some of their clinical and experimental cancer chemopre-
ventive effects via mechanisms that are independent of
COX inhibition.
In this issue of 
 
The Journal of Experimental Medicine
 
,
Zhang et al. provide additional compelling evidence for
COX-independent chemopreventive effects of NSAIDs
(5). They accomplish this by demonstrating that NSAID-
induced inhibition of cell transformation, inhibition of cell
proliferation, and initiation of apoptosis are not dependent
on the expression of COX isozymes. By genetic manipu-
lation of mouse embryos, they developed fibroblasts in
which COX-1 or COX-2 or both COX-1 and COX-2
mRNAs and proteins were absent. The resulting three
types of cell lines were equally capable of undergoing on-
cogenic transformation induced by 
 
ras
 
 and SV-40 onco-
genes. In addition, the proliferation of transformed versions
of these three cell types was inhibited and apoptosis was
stimulated equally by various NSAIDs. Both non-COX-
selective NSAIDs (i.e., sulindac, ibuprofen, piroxicam, and
indomethacin) and the selective COX-2 inhibitor, NS-398
produced these effects in all three types of cell lines. Thus,
targeted disruption of COX genes does not affect these
NSAID-induced events related to transformation and cell
turnover kinetics.
A few years ago, we demonstrated that NSAIDs inhib-
ited the proliferation and induced apoptosis in human co-
lon cancer cell lines (6, 7). Since this effect was obtained in
medium supplemented with serum rich in PGs, we pur-
sued this observation further to assess its dependence upon
PGs and COX. In due course, a colon cancer cell line,
HCT-15, which was intrinsically deficient in COX-1 and
COX-2 expression and failed to produce any prostanoids
even upon stimulation with arachidonic acid, mellitin, and
the calcium ionophore A23187 was identified (8). NSAIDs
had effects on proliferation and apoptosis in these cells sim-
ilar to those in cells that express both COX enzymes and
produce several PGs, such as HT-29. These observations,
reinforced by subsequent studies demonstrating that com-
pounds with meager COX inhibitory activity (e.g., sulin-
dac sulfone, and salicylic acid [SA]) also inhibit cell prolif-
eration and induce apoptosis in colonocytes, led to the
hypothesis that COX-independent mechanisms account
for at least some of the chemopreventive actions of 
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NSAIDs (3). A trivial explanation for our results and those
of Zhang et al. is that there exist additional undiscovered
COX isoforms that compensate for the loss of the known
cyclooxygenases. However, this is practically untenable,
because COX-1 and COX-2 null fibroblasts and HCT-15
 
cells do not produce PGs, a defining characteristic of COX
enzymes; as well, HCT-15 cells do not produce PGs even
upon stimulation. Regardless of this, the evidence should
and already has aroused suspicion that NSAIDs may induce
their chemopreventive effects by targeting other proteins
or pathways, beyond the cyclooxygenases. Because of the
probable importance of these proteins or pathways in pre-
venting neoplasia, many laboratories are now actively work-
ing to identify them.
Several selected observations regarding the antineoplastic
actions of NSAIDs are briefly reviewed below. They are
broadly classified into three major categories according to
their dependence on COX inhibition: (i) COX-dependent
or COX-related; (ii) COX-independent; and (iii) uncer-
tain, i.e., those that do not appear to involve COX, al-
though their COX independence is not yet proven (Table I).
 
COX-dependent Effects
 
For the antineoplastic effects of NSAIDs to be exerted
through COX inhibition, COX and PGs must contribute
substantially to colorectal carcinogenesis. Evidence that
eicosanoids and COX isozymes are important in colorectal
cancer development includes: (a) PGE
 
2
 
 levels are elevated
in colorectal tumors; (b) eicosanoids, including PGs, stimu-
late proliferation and reduce apoptosis in colonocytes; (c)
COX-2 is upregulated in colorectal tumors, more fre-
quently in cancers than adenomas; and (d) COX-2 contrib-
utes to colorectal tumorigenesis in 
 
APC
 
 knockout mice (9)
where APC
 
D
 
716(
 
1/2
 
)
 
COX-2
 
(
 
2/2
 
)
 
 mice develop fewer intes-
tinal tumors than do APC
 
D
 
716(
 
1/2
 
)
 
COX-2
 
(
 
2
 
/
 
1
 
)
 
 mice, which
in turn bear fewer tumors than do APC
 
D
 
716(
 
1/2
 
)
 
COX-2
 
(
 
1/1
 
)
 
mice (for review see reference 3). Aside from producing
several eicosanoids, COX may promote carcinogenesis by
activating carcinogens via its peroxidase activity, which can
operate on substrates other than PGG
 
2
 
; or by producing ei-
ther malondialdehyde, a direct-acting mutagen, or peroxyl
radicals (see Fig. 2).
Angiogenesis, which is important in carcinogenesis, is
related to PGs and COX. PGE
 
1
 
 and COX-2 induce angio-
genesis (10) and NSAIDs inhibit it (11). Clearly, inhibition
Figure 1. Colorectal carcinogenesis.
Normal epithelial cells acquire abnormal
growth and morphological characteris-
tics and form an aberrant crypt focus,
which enlarges to become an adenoma.
With time, adenomas increase in size
and can become adenocarcinomas,
which have the ability to invade and
metastasize. Presumably driving this pro-
cess are somatic mutations that develop
in the designated key genes in the
colonocytes that make up these lesions;
abnormalities in DNA mismatch repair
mechanisms can also contribute. Aspirin
and other NSAIDs inhibit this process,
perhaps at several distinct points. Figure
is adapted from reference 2.
Figure 2. Arachidonic acid metabolism by COX isoenzymes. Phos-
pholipase A2 (PLA2) releases arachidonic acid (AA) from membrane phos-
pholipids, which is in turn converted by either COX-1 or COX-2 to
PGG2 (C, cyclooxygenase catalytic activity of COX) and then to PGH2
(P, peroxidase catalytic activity of COX). PGH2 is converted to either
PGs (e.g., E2, F2a, I2, D2); thromboxane A2 (TxA2); or malondialdehyde
(MDA). MDA is a direct-acting mutagen and carcinogen and can be pro-
duced without COX by direct lipid peroxidation. AA can be converted
directly to 15-(R)-HETE by both COX isoenzymes. COX-1 is constitu-
tively expressed in most tissues, whereas COX-2 is induced by cytokines,
growth factors, tumor promoters, or other agents after the initiation of
specific physiological events. Compounds other than PGG2, e.g., procar-
cinogenic hydroperoxides, can serve as substrates for the peroxidase activ-
ity of both COX enzymes. Inactive carcinogens serving as electron ac-
ceptors can also become activated by this activity. The COX isoenzymes
are also involved in the formation of peroxyl radicals that can activate
procarcinogens. Figure is adapted from reference 3. 
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of angiogenesis could explain the ability of NSAIDs to re-
gress adenomas in familial adenomatous polyposis (FAP)
patients and to inhibit colorectal adenocarcinoma forma-
tion. However, like most if not all of the mechanisms dis-
cussed here, it has yet to be formally demonstrated in vivo
that angiogenesis mediates the chemopreventive effects of
NSAIDs in colorectal cancer. It is noteworthy that sulindac
sulfone also inhibits angiogenesis (12). This raises the possi-
bility of PG- or COX-independent mechanisms of angio-
genesis as well.
Whether COX or eicosanoids are necessary or essential
for colorectal carcinogenesis has not been fully assessed.
Clearly, some colorectal cancers develop without overex-
pressing COX or producing high levels of PGs. However,
this still does not rule out a central role for COX enzymes,
at least for most colorectal cancers.
 
COX-independent Effects
Cell Turnover.
 
A potentially important means by which
NSAIDs prevent colorectal neoplasia is to affect cell turn-
over in the colorectal epithelium. Cell death and renewal
are critical for the regulation of the structural integrity of all
tissues. The growth rate of a tissue or a tumor is deter-
mined by the rate of proliferation and counterbalanced by
the rates of cell loss by apoptosis or necrosis of the cells that
comprise them. We and others have shown that several
NSAIDs, including SA, ASA, sulindac (and its metabolites
sulindac sulfide and sulindac sulfone), indomethacin, pi-
roxicam, naproxen, as well as selective COX-2 inhibitors,
retard the proliferation and induce apoptosis in colon can-
cer cells (3, 13).
Human studies assessing the effects of NSAIDs on co-
lonocytic proliferation have generated conflicting results,
with sulindac reported either to show no effect upon pro-
liferation or to reduce it (3). Apoptosis is suppressed in spo-
radic colorectal adenomas and carcinomas and in the flat
mucosa or adenomas of patients with FAP. In FAP patients,
sulindac normalizes apoptosis in normal rectal mucosal
colonocytes while reducing the size and number of their
 
adenomas (for review see reference 3). Thus, it is possible,
but not yet fully substantiated, that cell kinetic effects play a
major role in the antineoplastic effects of these compounds.
As we have shown previously, and as is now described
in additional detail by Zhang et al., these events in vitro
are clearly not dependent upon the expression of COX
isozymes (5, 8). NSAIDs inhibit cell proliferation by induc-
ing cell cycle quiescence in colonocytes, in part by reduc-
ing the levels of several key molecules that catalyze transi-
tions through the various phases of the cell division cycle
(3, 6, 7). However, the detailed molecular pathways that
induce quiescence have yet to be fully elucidated.
Several groups contend that they have identified mecha-
nisms by which NSAIDs induce PG- or COX-independent
apoptosis. Preliminary reports claim that sulindac sulfone in-
duces this form of cell death by inhibiting cGMP-dependent
phosphodiesterase 5 (14). Others have shown that NSAID
treatment of colon cancer cells generates the proapoptotic
lipid, ceramide (15). By blocking the biosynthesis of pros-
tanoids, NSAIDs increase the intracellular levels of arachi-
donic acid, which activates neutral sphingomyelinase, which
in turn converts sphingomyelin to ceramide. Strictly speak-
ing, this is a PG-independent mechanism, but, as pre-
sented, this model of ceramide formation is dependent
upon COX inhibition and therefore may not explain the
apoptosis induced by sulindac sulfone or SA, nor that in-
duced in COX null cells, like HCT-15 or those generated
by Zhang et al.
 
Cell Transformation.
 
Aside from Zhang et al., other
groups have also reported that NSAIDs inhibit cell trans-
formation. Dong et al. showed that salicylates inhibited
phorbol ester (TPA)-induced transformation of mouse epi-
dermal JB6 cells (16). Hermann et al. demonstrated that
sulindac sulfide inhibited transformation of primary rat em-
bryo fibroblasts by activated H-ras and SV40 T antigen or
other transformation-inducing stimuli (17). In both cases,
transformation was inhibited at drug concentrations below
those required to inhibit cell proliferation or cell viability.
Dong et al. proposed that AP-1 activation is important for
 
Table I.
 
Mechanisms Inﬂuenced by NSAIDS That May Contribute to Their Antineoplastic Effects
 
COX-dependent COX-independent
COX dependence 
unclear
Cell turnover Cell turnover Tumor immunity
proliferation/apoptosis proliferation/apoptosis Myc transcription
Carcinogen formation Cell transformation PPAR activation
Angiogenesis DNA repair
Angiogenesis
Ras signal transduction
MAP kinase activation
NF-
 
k
 
B activation
The table shows the cellular or molecular mechanisms influenced by NSAIDs that may contribute to their antineoplastic effects, classified in relation
to their dependence on inhibition of cyclooxygenase catalytic activity. 
448
 
Commentary
 
this effect of salicylates. This process appeared to be inde-
pendent of PG inhibition, as indomethacin could not in-
hibit TPA-induced transformation, nor AP-1 activity. Mi-
togen-activated protein (MAP) kinase was shown not to be
involved in this process. Hermann et al. proposed that
sulindac sulfide inhibits oncogenic cell transformation by
directly inhibiting Ras signaling. They showed that sulin-
dac sulfide binds noncovalently to Ras and inhibits Ras-
dependent Raf binding and Raf activation without affect-
ing its GTPase or GTP binding activity.
Apart from its role in cell transformation, Ras influences
many pathways potentially important for the chemopre-
ventive activity of NSAIDs, and thus it may be a pivotal
target molecule integrating several disparate pathways in-
fluenced by NSAIDs. Inhibition of Ras signaling may also
explain the effects of NSAIDs on proliferation and apopto-
sis at higher drug concentrations. Ras inhibition may link
the effect of NSAIDs to NF-
 
k
 
B and MAP kinase activity
(see below) (18). Modulation of Ras activity by NSAIDs
may also relate to the eicosanoid pathway, as arachidonic
acid and PGs regulate Ras regulatory proteins such as
p120GAP and NF-1GAP (19).
 
DNA Repair.
 
Both ASA and nonsalicylate NSAIDs re-
duce microsatellite instability in colon cancer cell lines defi-
cient in DNA mismatch repair (i.e., HCT-116, HCT-15,
SW48, and LoVo cells) (20). Mismatch repair–deficient
cells with mutations in hMLH1, hMSH2, or hMSH6, but
not with a hPMS2 mutation, die selectively by apoptosis in
response to NSAID treatment. Given that HCT-15 cells
were used in this study, which we found to be deficient in
COX expression (8), this effect is also likely to be COX in-
dependent. However, Rüschoff et al. (20) did not directly
confirm the absence of COX isozymes or PG production
in the cells they used. Patients with hereditary nonpolypo-
sis colorectal cancer have germline mutations in DNA mis-
match repair genes. Therefore, it was speculated that
NSAIDs could prevent colon cancer in most of these pa-
tients. However, the clinical efficacy of NSAIDs in this
particular high-risk group remains unknown.
 
MAP Kinases.
 
SA activates p38 MAP kinase and in-
duces apoptosis
 
 
 
in FS-4 fibroblasts, and both are inhibited
by the p38 MAP kinase inhibitor SB-203580. p38MAP ki-
nase activation may also be important for inhibition of nu-
clear factor (NF)-
 
k
 
B by SA (21).
 
NF-
 
k
 
B.
 
ASA and SA, but not indomethacin, inhibit
NF-
 
k
 
B activation (21, 22). There is evidence that these
compounds bind to and inactivate I
 
k
 
B kinase 
 
b
 
, which in
turn prevents the degradation of I
 
k
 
B and the subsequent
translocation of NF-
 
k
 
B to the nucleus, where it activates
the transcription of a variety of genes (22). Depending on
the cell type and the circumstances, NF-
 
k
 
B augments or
inhibits apoptosis. Inhibition of the proliferation of 
 
ras
 
-
transformed rat fibroblasts by ASA may also be related to
inhibition of NF-
 
k
 
B activation (18).
To show that activation of MAP kinases or inhibition of
NF-
 
k
 
B activation are COX-independent processes, Yin et
al. demonstrated that each is influenced exclusively by
 
salicylates, and not by indomethacin (22). However, in-
domethacin and other nonsalicylate NSAIDs prevent colon
neoplasias and regress adenomas in FAP patients. As a re-
sult, it is unlikely that these two processes, as delineated in
these experiments, play a major role in the chemopreven-
tive effects of NSAIDs.
 
Role of COX Unclear
 
The observations that follow relate to processes that do
not appear related to PGs or COX inhibition. However,
since they have not been examined in detail in cells that
lack COX enzymes or PG production, their relationship to
COX and/or arachidonic acid metabolism remains uncer-
tain.
 
Myc/src Oncoproteins.
 
Lu
 
 
 
et al. found that, in addition to
apoptosis, Myc was markedly induced in serum-starved
chicken embryo fibroblasts after activation of pp60
 
v-src
 
 and
NSAID treatment. Apoptosis was markedly inhibited by
transfection of antisense 
 
myc 
 
(23). Similar results were
found in other cancer cell lines.
 
Peroxisomal Proliferator-activated Receptors.
 
Peroxisomal pro-
liferator-activated receptors (PPARs) are a group of nuclear
hormone receptor protein transcription factors that, when
stimulated, induce differentiation of fibroblasts to adipo-
cytes. PPAR-
 
g
 
 receptors are expressed in the colon and to
an even greater degree in colon tumors (24). Activation of
PPARs in colon cancer cells reduces their growth and in-
duces differentiation in vitro (25). Interestingly, in-
domethacin and selected, but not all, NSAIDs bind to and
activate PPAR-
 
g
 
 receptors (26). However, piroxicam,
which regresses colorectal polyps in humans and animals,
does not bind PPAR-
 
g
 
 as effectively as other NSAIDs (26)
and PPAR-
 
g
 
 activators, such as troglitazone, increase colon
tumors in APC
 
Min
 
 mice (27, 28). These latter data suggest it
is unlikely that PPAR activation is important for the
chemoprevention of colorectal cancer by NSAIDs.
 
Tumor Immunity.
 
There is ample indirect evidence for
a role of NSAIDs, and by extension of COX enzymes, in
immune phenomena related to various cancers. A clearly
studied case concerns their role in the expression of HLAs,
which is altered in many cancers and frequently downregu-
lated in colon cancer (3). Such abnormalities may adversely
affect the clinical course of cancer and the outcome of T
cell–based immunotherapy.
NSAIDs may boost mechanisms of tumor immune sur-
veillance; tumors are hypothesized to escape from im-
mune-mediated destruction by thwarting mechanisms that
detect tumor-associated antigens. Class I and II HLA anti-
gens, participating in antigen presentation, may be critical
to this process. The role of NSAIDs in these processes has
been assessed in animal models of colon cancer and in cell
culture systems. Piroxicam upregulates the expression of
MHC genes in the colonic mucosa of rats treated with a
carcinogen (3). PGE
 
2 
 
reduces the transcription of HLA class
II molecules and NSAIDs can increase it (29). That such
effects occur in the presence of PG-rich serum in cell cul-
ture systems indicates, along with additional evidence (Ri- 
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gas, B., unpublished observations), that this is probably an-
other COX-independent effect of NSAIDs. That NSAIDs
can induce the expression of the suppressed HLA genes in
colorectal neoplasias suggests that these versatile compounds
may restore the ability of the immune system to eliminate
transformed cells.
As this brief overview demonstrates, multiple processes
with their attendant molecular pathways have been pro-
posed to mediate the chemopreventive effects of NSAIDs
(Table I). The NSAIDs, highly protein bound molecules,
probably interact with and inhibit the function of many
proteins and, perhaps, other macromolecules. To compli-
cate matters, it is not clear whether the key in vitro effects
of NSAIDs that were discussed earlier, such as cell transfor-
mation, cell growth, or angiogenesis, are at all relevant to
colorectal cancer chemoprevention.
Some of the data reviewed here indicate that COX inhi-
bition by NSAIDs is indeed required for their chemopre-
ventive effect. However, another body of data, including
that of Zhang et al. in this issue (5),
 
 
 
make the equally
strong case that COX inhibition is not required for certain
presumed chemopreventive effects of NSAIDs. This appar-
ent inconsistency is not merely of theoretical interest, but
has important implications for the rational design of strate-
gies for colon chemoprevention and for assessing the rela-
tive significance of each mechanism in carcinogenesis. In all
likelihood this is not a contradiction at all; rather, NSAIDs
bring about their chemopreventive effects in the colon
through both COX-dependent and -independent mecha-
nisms. Indeed, we have proposed a model that assumes both
mechanisms operate to produce the clinical antineoplastic
effects of NSAIDs, in which COX-dependent and -inde-
pendent pathways modulate different stages of the multi-
step process of colon carcinogenesis or different events reg-
ulating each stage (30). The multiplicity of action of NSAIDs,
if confirmed, could in fact explain their high degree of ef-
fectiveness in colon cancer prevention in humans.
The great challenge will be to determine which of these
or other yet unknown mechanisms produce the remarkable
anticancer effect of NSAIDs, as well as the relative contri-
bution of each. If and when these key questions are worked
out, then a great deal will have been learned about colorec-
tal carcinogenesis. In addition, new tools will have been
collected to identify new compounds that hold promise to
prevent colorectal cancer more safely and effectively than
the conventional NSAIDs.
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